In 2020, the USFDA approved an intrauterine vacuum-induced hemorrhage control device to treat postpartum hemorrhage. Researchers from 16 hospitals in the USA tested this device on 800 individuals to determine its safety and efficiency in a real-world setting. The device successfully controlled hemorrhage caused by uterine atony in both vaginal (92.5%) and cesarean (83.7%) births. The device controlled the hemorrhage in 73.8% of vaginal birth patients and 62.2% of cesarean birth patients in ≤5 min .
The indwelling time of the device in the uterus is 4.6 hours for vaginal births and 6.3 hours for cesarean births. The bleeding recurred in 2.8% and 4.1% of patients with vaginal and cesarean births, respectively. The study confirms the safety and effectiveness of the device in managing postpartum hemorrhage in both vaginal and cesarean births. Can this vacuum-induced hemorrhage control…
